Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Michael Schifano

Obstetrics Marion, IL Doctor of Osteopathy

NPI 1679507818 CMS profile 257829

3408 Office Park Dr, Marion, IL 62959

Open in the dashboard

General payments

$1,388

77 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Michael Schifano of Marion, IL is reported in the CMS Open Payments database as having received $1,388 across 77 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 66th percentile of Obstetrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $176 11
2024 General $276 14
2023 General $411 23
2022 General $173 9
2021 General $32 2
2019 General $320 18

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Michael Schifano
  • Obstetrics median
  • Middle half of Obstetrics
  • National median

In program year 2025, general payments to Michael Schifano were reported at $176. Among 649 Obstetrics profiles paid that year, the median was $181 and the middle half received between $61 and $424.

Show as a table
Year Michael Schifano Obstetrics median Middle half National median
2019 $320 $177 $60–$381 $163
2020 $0 $92 $35–$201 $114
2021 $32 $125 $40–$351 $132
2022 $173 $186 $65–$448 $149
2023 $411 $183 $61–$451 $160
2024 $276 $176 $62–$406 $164
2025 $176 $181 $61–$424 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Organon LLC $278 16 payments
  2. Allergan Inc. $117 9 payments
  3. Sumitomo Pharma America, Inc. $108 6 payments
  4. Astellas Pharma US Inc $85 4 payments
  5. Bayer HealthCare Pharmaceuticals Inc. $84 5 payments
  6. AbbVie, Inc. $81 4 payments
  7. Exeltis, USA Inc. $79 5 payments
  8. Sage Therapeutics, Inc. $78 3 payments
  9. Mayne Pharma Inc. $71 4 payments
  10. Covidien LP $43 1 payment
  11. Other $363 20 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $1,369 76 payments
  2. Education $19 1 payment
Products named General payments · program years 2019–2025
  1. NEXPLANON $263 15 payments
  2. MYFEMBREE $89 5 payments
  3. Veozah $85 4 payments
  4. LO LOESTRIN FE $82 6 payments
  5. ZURZUVAE $78 3 payments
  6. TAYTULLA $69 5 payments
  7. Kyleena $67 4 payments
  8. Mirena $67 4 payments
  9. SLYND $47 3 payments
  10. TruClear $43 1 payment
  11. Other $608 33 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 7 drugs

Part D claims

225

Median for Obstetrics & Gynecology: 65

Drug cost

$20,723

Median for Obstetrics & Gynecology: $3,585

Branded share of claims

52%

Median for Obstetrics & Gynecology: 25.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 20 $15,339
Estradiol Generic 59 $2,146
Oxybutynin Chloride Er Oxybutynin Chloride Brand 67 $1,435
Solifenacin Succinate Generic 33 $1,305
Progesterone Progesterone, Micronized Brand 19 $336
Medroxyprogesterone Acetate Generic 16 $140
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 11 $22

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 24,311 Part D prescribers listed as Obstetrics & Gynecology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$17,747

Medicare's payments for the services billed

Medicare patients

66

Average age 67

Services billed

169

66 women, 0 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 58%
Arthritis 38%
Depression 29%
Diabetes 23%
Osteoporosis 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Veozah
  • Astellas Pharma US Inc $42
$42 — —
ZEPBOUND
  • Lilly USA, LLC $16
$16 — —
MYFEMBREE
  • Sumitomo Pharma America, Inc. $15
$15 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

77 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Obstetrics in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record